

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: 8/21/1985
Gender: Female
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 00/00/0000 00:00

UDP Glucuronosyltransferase 1A1 (UGT1A1) Genotyping

ARUP test code 0051332

UGT1A1 Genotyping Specimen	whole blood
UGT1A1 Genotyping Allele 1	(TA)7 or *28 *
UGT1A1 Genotyping Allele 2	(TA)7 or *28 *
UGT1A1 Genotyping Interpretation	See Note

Section 79-L of New York State Civil Rights Law requires informed consent be obtained from patients (or their legal guardians) prior to pursuing genetic testing. These forms must be kept on file by the ordering physician. Consent forms for genetic testing are available at www.aruplab.com. Incidental findings are not reported unless clinically significant but are available upon request.

Indications for ordering:
- Determine sensitivity to irinotecan or related compounds.
- Confirm a diagnosis of Gilbert Syndrome.

Homozygous UGT1A1 (TA)7: Two copies of the UGT1A1 *28 (TA)7 variant were detected predicting a poor metabolizer status. This is associated with decreased UGT1A1 enzyme and increased risk for irinotecan toxicity, namely, neutropenia and diarrhea. Dose reduction is recommended. This genotype has been reported to be associated with Gilberts syndrome (benign familial hyperbilirubinemia).

This result has been reviewed and approved by [REDACTED]

H=High, L=Low, *=Abnormal, C=Critical

BACKGROUND INFORMATION: UDP Glucuronosyltransferase 1A1 (UGT1A1) Genotyping

CHARACTERISTICS: UGT1A1 is responsible for the clearance of drugs (e.g., irinotecan) and endobiotic compounds (e.g., bilirubin). Irinotecan's major active and toxic metabolite (SN-38) is inactivated by the UGT1A1 enzyme and then eliminated via the bile. UGT1A1 gene mutations cause accumulation of SN-38, which may lead to irinotecan-related toxicities (neutropenia, diarrhea).

CAUSE: Variations in TA repeat number in the TATAAA element of the 5'UGT1A1-promoter affects transcription efficiency. The common number of repeats is six [(TA)6, *1 allele], while seven repeats [(TA)7, *28 allele] is associated with reduced transcription activity. Homozygosity for the (TA)7 allele is also associated with Gilbert syndrome (benign familial hyperbilirubinemia).

ALLELES TESTED: *36 allele, (TA)5; *1 allele, (TA)6; *28 allele, (TA)7 and *37 allele, (TA)8.

CLINICAL SENSITIVITY/SPECIFICITY: Risk of irinotecan toxicity by genotype (Br J Cancer. 2004; 91:678-82).

6/6 (*1/*1): diarrhea 17 percent; neutropenia 15 percent

6/7 (*1/*28): diarrhea 33 percent; neutropenia 27 percent

7/7 (*28/*28): diarrhea 70 percent; neutropenia 40 percent

ALLELIC FREQUENCY:

*1(TA)6: Whites 0.61, Asians 0.84, African Americans 0.47

*28(TA)7: Whites 0.39, Asians 0.16, African Americans 0.43

METHODOLOGY: Polymerase chain reaction followed by size analysis using capillary electrophoresis.

ANALYTICAL SENSITIVITY AND SPECIFICITY: Greater than 99 percent.

LIMITATIONS: Variations in the UGT1A1 gene, other than those targeted, will not be detected. Clinical significance of the rare *36, (TA)5 and *37, (TA)8 alleles in predicting irinotecan toxicities is not well established. Genetic and non-genetic factors other than UGT1A1, may contribute to irinotecan toxicity and efficacy. Diagnostic errors can occur due to rare sequence variations.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

EER UGT1A1

See Note

[REDACTED]

[REDACTED]

H=High, L=Low, *=Abnormal, C=Critical

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
UGT1A1 Genotyping Specimen	24-235-101039	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
UGT1A1 Genotyping Allele 1	24-235-101039	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
UGT1A1 Genotyping Allele 2	24-235-101039	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
UGT1A1 Genotyping Interpretation	24-235-101039	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
EER UGT1A1	24-235-101039	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 24-235-101039
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 3 of 3 | Printed: 8/27/2024 12:12:10 PM
4848